Organon to present data from Phase 3 ADORING 1, ADORING 2 trials

Organon (OGN) will present results from a sub-analysis of pooled data from the Phase 3 ADORING 1 and ADORING 2 trials evaluating VTAMA cream versus vehicle at the 2025 American College of Allergy, Asthma & Immunology, ACAAI, Annual Scientific Meeting in Orlando, Florida, on November 8, 2025. Notable findings include: Early improvements in skin clearance were observed, with significant differences in vIGA-AD response rates as early as week 1 and maintained through week 8 in children with or without atopic comorbidities; Improvement in eczema severity, as measured by EASI scores, was observed as early as week 2 and sustained through week 8; Improvements in patient-reported outcomes, including sleep, as measured by total mean Patient-Oriented Eczema Measure and mean POEM sleep scores, were noted as early as week 1 and maintained through week 8. Clinically meaningful improvements in itch were observed at week 2, based on responder analysis, with continued improvement through week 8.